Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

NCT05422508 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Varicella

Interventions

BIOLOGICAL: MG1111 (BARICELA)
BIOLOGICAL: VARIVAX
BIOLOGICAL: Suduvax

Sponsor

Green Cross Corporation